![](https://endpts.com/wp-content/uploads/2017/07/protocols-two.jpg)
Takeda's Alunbrig wins lung cancer approval; Atara offers another positive MS drug update
→ Takeda’s tyrosine kinase inhibitor brigatinib (branded Alunbrig) — a drug the Japanese drugmaker acquired with its $5.2 billion Ariad buyout — has secured approval for a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.